Metabolic dysfunction, antidiabetic drugs, and asthma: bibliometric evidence, emerging trends, and translational frontiers from 2006 to 2025
Abstract
Background: The association among metabolic dysfunction, antidiabetic drugs, and asthma has attracted increasing attention in recent years. However, the knowledge structure, dominant metabolic mechanisms, drug-related research hotspots, and clinical translational evidence in this interdisciplinary field remain insufficiently characterized.
Methods: This study conducted a bibliometric evidence-mapping and visualization analysis of research linking metabolic dysfunction, antidiabetic drugs, and asthma published between 2006 and 2025. Data were obtained from the Web of Science Core Collection, Scopus, and PubMed. Bibliometric and visualization methods were used to identify global research trends, major knowledge domains, thematic evolution, and emerging translational frontiers.
Results: A total of 1, 502 records from the Web of Science Core Collection, 6, 710 records from Scopus, and 38 PubMed-indexed clinical studies were included. Publication output showed an overall upward trend, with a marked increase in research attention after 2015. Keyword and clustering analyses indicated that obesity, insulin resistance, metabolic syndrome, inflammation, oxidative stress, adipokines, lung function, and airway hyperresponsiveness formed the dominant knowledge base of this field. In contrast, drug-related topics, including metformin, peroxisome proliferator-activated receptor γ agonists, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and dipeptidyl…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.